Indian generics makers claim victory in anaemia drug patent feud

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Indian generics makers claim victory in anaemia drug patent feud

Generic drug.jpg

The Delhi High Court said third parties who use different processes to make a patented product can’t be restricted if the plaintiff’s registration covers a product-by-process patent

The Delhi High Court has denied Swedish drug maker Vifor Pharma’s application to prevent four Indian companies from launching generic versions of its iron-deficiency anaemia drug.

Justice Jyoti Singh ruled on Monday, July 24, that a drug patent only covering process claims could not be used to restrict third parties who derived the same compound through different methods.

The decision marks the first time the court has delved into what constitutes a product-by-process claim.

Vifor had claimed that its patent covered a product featuring ‘ferric carboxymaltose’ (FCM) as well as a process to prepare it. The Swedish drugmaker sells its FCM products in India under the brand names Ferinject, Injectafer and Revofer.

The company argued that its patent was actually for a product even though it described a process. Therefore, irrespective of the defendants’ process, any FCM production would infringe its patent.

However, defendants Dr Reddy’s Laboratories, MSN Laboratories, Corona Remedies, and Virchow Biotech claimed that Vifor’s invention was limited to a product obtained through the specific process mentioned in its patent application.

The court sided with the defendants and found that Vifor’s claims covered a product-by-process patent. It said the process terms were limitations to, and not additional features of, the rights granted to the company.

The court held that Corona and Virchow's products were different from Vifor’s and not infringing. It also found that the processes claimed by Dr Reddy’s and MSN were outside the scope of Vifor’s process and so were also non-infringing.

Corona had already placed its product on the market in 2020. This week’s decision paves the way for the other three companies to launch their products before Vifor’s patent expires in October.

more from across site and SHARED ros bottom lb

More from across our site

A new foundation in Chile is giving women in the IP community the mentorship, and visibility they’ve long lacked
The EUIPO is keen to stress the benefits of mediation as a means of resolving IP disputes, but do roadblocks remain?
Åsa Gustafson, global patent paralegal manager at Zacco, provides insight into the world of a paralegal, explains how she keeps abreast of legal developments, and reveals a passion for weaving
Alif Gultom and Andrew Diamond of Januar Jahja & Partners explain why Indonesia must adopt reforms against bad-faith filings and safeguard its trademark system for the future
In the third episode of a podcast series celebrating the tenth anniversary of IP Inclusive, we discuss the ‘Women in IP’ network and the current state of diversity within the profession
Practitioners, including two ex USPTO directors, say the Patent Eligibility Restoration Act could restore clarity and predictability to US patent law, though concerns remain
News of an alliance between two Malaysian law firms and the launch of a self-help video aimed at supporting IP professionals through menopause were also among the top talking points
Speakers at the EUIPO’s IP Mediation Conference discussed how lawyers can act in tandem with clients during mediation, and the importance of showing a united front
A report that revealed top legal LinkedIn influencers are generating hundreds of thousands in advertising value is the push lawyers need to up their social media presence
Speakers at the EUIPO’s Mediation Conference say mediation can offer a ‘cathartic’ and effective alternative to litigation that IP owners should consider
Gift this article